<DOC>
	<DOCNO>NCT00488527</DOCNO>
	<brief_summary>To evaluate efficiency Lantus plus combine oral hypoglycaemic agent term respondent percentage . The respondent define person achieve value final determination HbA1c &lt; 7 % absolute value and/or decrease final value HbA1c 12 % compare initial value ( final HbA1c vs. initial HbA1c ) . Describe glycemia level body weight change two response group , ( respondent non-respondents ) . Describe adverse event Evaluate safety use medication accord incidence relevance hypoglycemia event , ( symptomatic , diurnal , nocturnal , severe ) . Estimate intra-patient variability fasting glycemia</brief_summary>
	<brief_title>DOMME Dose Optimization Multicentric Mexican Evaluation</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Patients type 2 diabetes mellitus receive antidiabetic treatment ( 1 2 oral agent ) 6 month , need prolong action basal insulin control hyperglycemia Glycosylated hemoglobin &gt; 8,0 % &lt; 10 % Body mass index ( BMI ) &lt; 40 kg/m2 Voluntary acceptation treatment capability self inject insulin glargine Capability desire carry selfdetermination glycemia level use glucometers Renal function disorder , reveal serum creatinine &gt; 177 Âµmol/l ( &gt; 2,0 mg/dl ) Visit 1 currently undergo kidney dialysis Acute metabolic acidosis ( &gt; 1 episode last year ) chronic , include diabetic ketoacidosis Clinical evidence active liver disease serum ALT/AST &gt; 2.5 time upper normality limit A history unnoticed hypoglycemia Surgical treatment diabetic retinopathy , ( laser photocoagulation vitrectomy ) , three month prior join trial , patient need treatment within three month enter trial Pregnancy breast feed Not use adequate birth control method , ( potentially fertile female ) : example , use systemic hormone , ( pill birth control implant ) , intrauterine device barrier method , ( diaphragm intravaginal spermicide , male female preservative ) Known hypersensitivity insulin glargine excipients Malignant process , except basal carcinoma cell last five year More two week continuous treatment systemic glucocorticoid last 6 month Concomitant treatment noncardio selective beta blocker Known suprarenal failure Known hemoglobinopathy anemia , uncontrolled unstable A psychiatric disturbance prevents patient understanding nature , objective possible consequence trial A history drug alcohol abuse last two year current addiction Current use insulin glargine Any clinically relevant , cardiovascular , hepatic , neurological , endocrinal systemic major disease , type , may hinder development protocol interpretation result trial Known existence GAD ( glutamic acid decarboxylase ) antibodies Type 1 diabetes mellitus , accord definition WHO The use drug research insulin six month prior join trial use insulin study four week enter trial A history severe hypoglycemia repeat blackout , ( 1 ) , last year The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2010</verification_date>
</DOC>